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Coactivator recruitment by activation function 2 (AF2) in the steroid receptor ligand binding domain takes
place through binding of an LXXLL amphipathic -helical motif at the AF2 hydrophobic surface. The andro-
gen receptor (AR) and certain AR coregulators are distinguished by an FXXLF motif that interacts selectively
with the AR AF2 site. Here we show that LXXLL and FXXLF motif interactions with steroid receptors are
modulated by oppositely charged residues flanking the motifs and charge clusters bordering AF2 in the ligand
binding domain. An increased number of charged residues flanking AF2 in the ligand binding domain com-
plement the two previously characterized charge clamp residues in coactivator recruitment. The data suggest
a model whereby coactivator recruitment to the receptor AF2 surface is initiated by complementary charge
interactions that reflect a reversal of the acidic activation domain-coactivator interaction model.
Nuclear receptors are hormone-dependent transcription
factors that bind steroids and other hormones, such as thyroid
hormone, retinoic acid, and vitamin D, to regulate cell prolif-
eration and differentiation, development, and homeostasis.
Steroid receptors share a modular arrangement of structurally
conserved domains, including the ligand binding domain
(LBD) in the carboxyl-terminal region, a central DNA binding
domain, and a variable NH2-terminal region (8). Most recep-
tor LBDs are transcriptionally active when bound to agonist,
an activity that results from activation function 2 (AF2). NH2-
terminal regions of some receptors also contain the transacti-
vation domain, activation function 1. While the structural basis
for coactivator recruitment by activation function 1 is largely
unknown, studies have indicated a general mechanism for
AF2.
Nuclear receptors interact with p160 coactivators through
the AF2 region of the LBD (16, 51). AF2 resides in a hydro-
phobic cleft created by helices 3, 4, 5, and 12. The hydrophobic
residues that comprise AF2 were initially identified as a coac-
tivator binding site by scanning surface mutagenesis of the
thyroid hormone receptor (TR) (14) and confirmed in coc-
rystal structures (3, 11, 45, 50). Agonist binding induces a
conformational shift in helix 12 (43) that completes the AF2
hydrophobic surface (11, 14), allowing p160 coactivator
LXXLL motif binding (11, 23). Binding of certain ligands can
alter the position of helix 12, thereby changing the specificity
for LXXLL motif binding. For example, ER binding of ralox-
ifene, a tissue-selective synthetic estrogen antagonist (5), or
4-hydroxytamoxifen (50) causes helix 12 to bind the core static
region of the AF2 hydrophobic groove, whereas in the pres-
ence of the agonist 17-estradiol, helix 12 contributes to the
recognition surface of AF2 for LXXLL motif binding. AF2
recruits the p160 coactivators steroid receptor coactivator 1
(SRC1), transcriptional intermediary factor 2 (also known as
TIF2, SRC2, and GRIP1), and steroid receptor coactivator 3
(also known as SRC3, TRAM1, ACTR, AIB1, RAC3, and
p/CIP) (16, 41), which are reported to have intrinsic histone
acetyltransferase activity and associate with p300 and CBP,
coactivators with more potent acetyltransferase activity (9, 46,
52). Accumulation of acetylase activity at enhancer-promoter
regions of regulated genes results in histone modification and
chromatin remodeling to facilitate transcription initiation (16,
41).
In contrast to other nuclear receptors, the AF2 region of the
androgen receptor (AR) is a weak-interaction site for LXXLL
motifs of p160 coactivators and preferentially binds an FXXLF
motif that is present in the AR NH2-terminal region and in
certain coregulators shown to associate with AR in the pres-
ence of androgen (19–20, 64). Like the LXXLL motif, inter-
actions of the AR NH2-terminal FXXLF and the FXXLF
motifs of AR-associated proteins involve binding of a con-
served amphipathic -helix with the complementary hydropho-
bic surface of AF2. Other protein-protein interaction motifs
similar to the AR FXXLF motif have been described, such as
FXXLW, required for p53-MDM2 complex formation (33),
and FXXAL, required for the interaction of VP16 with
TAFII31 (55). These signature motifs of gene-regulatory pro-
teins provide specificity in protein-protein interactions. In-
deed, the AR FXXLF motif binding is specific for the AF2
region of AR and mediates a strong androgen-dependent,
NH2-terminal interaction with the carboxyl-terminal region
(N/C interaction) (19) which is required for AR transactivation
of androgen-regulated genes, such as prostate-specific antigen
(21). While the FXXLF motif is predicted to form an -helical
structure that resembles the LXXLL motifs of p160 coactiva-
tors, it was not known what features of these -helical regions
initiate the interaction and establish the polarity of binding at
the AF2 surface. In this report we show that binding of FXXLF
and LXXLL to the AF2 of steroid receptors depends on clus-
ters of charged residues flanking the AF2 interface and oppo-
sitely charged residues flanking the -helical motifs. In addi-
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tion, we show that interaction of the AR FXXLF motif with
AF2 is attenuated by a conserved positively charged arginine
residue flanking the FXXLF binding motif. The data suggest
that multiple charge interactions initiate and modulate contact
with the AF2 surface and serve to position the -helical motifs
for subsequent hydrophobic interactions at the core of AF2.
We propose a charge polarity mechanism for AF2 recruitment
of the LXXLL motifs of p160 coactivators and the FXXLF
motifs in AR coregulators that represents a reversal of the
acidic activation domain-coactivator recruitment model.
MATERIALS AND METHODS
Plasmids. GAL4-DNA binding domain peptide fusions were constructed as
described previously (20) by annealing complementary oligonucleotides and
cloning into pGALO expressing the Saccharomyces cerevisiae GAL4 DNA bind-
ing domain amino acid residues 1 to 147. The GAL-AR624-919 and VP-AR1-660
mutants were created using a double PCR mutagenesis strategy where the VP
fusion proteins contain VP16 activation domain residues 411 to 456. pCMX-
hRXR was provided by Ronald M. Evans, the Salk Institute for Biological
Studies. pCMX-VP-F-hTR was provided by David D. Moore, Baylor College of
Medicine. VP16-PR-A, VP16-ER-LBD, pVP16-ER, pVP16-VDR, and the
luciferase reporter 5XGAL4-Luc3 were provided by Donald P. McDonnell,
Duke University.
Cell culture and two-hybrid assays. Human hepatocellular carcinoma HepG2
cells were obtained from the American Type Culture Collection and maintained,
transfected, and analyzed for luciferase activity as described previously (20).
Ligand dissociation rate studies were performed with COS cells as described
previously (19). The two-hybrid assay for interactions between GAL4 fusion
peptides and full-length AR or VP16 fusion proteins was previously described
(19, 34, 35).
AR LBD purification and isothermal titration calorimetry. The AR LBD
(amino acid residues 663 to 919) was expressed as a glutathione S-transferase
(GST) fusion protein from pGEX-KG in Escherichia coli BL21(DE3) in the
presence of 10 M dihydrotestosterone (DHT). GST-AR-LBD was purified by
affinity chromatography on glutathione-Sepharose and released from GST by
digestion with thrombin as described previously (39) except that phosphate-
buffered saline was used as the sonication and thrombin digestion buffer.
Isothermal titration calorimetry measurements were performed using an
OMEGA titration microcalorimeter from Microcal (Northampton, Mass.) at the
University of North Carolina Macromolecular Interactions Facility. Peptides
were synthesized by the Peptide Synthesis Facility of the University of North
Carolina and purified by high-performance liquid chromatography. The AR
LBD and synthetic peptides were dissolved in phosphate-buffered saline, and
measurements were performed at 26°C. Successive 5-l aliquots of peptide (0.2
to 1 mM) were added to a solution containing a fixed amount of AR LBD (10 to
20 M). Each titration experiment consisted of 30 to 50 injections of peptide into
the calorimetric sample cell containing 1.34 ml of purified AR LBD protein
solution. The thermal effect in calories of each addition was recorded, and the
data were fit by least-squares regression using ORIGIN software (Microcal). The
experimental approach provides a measure of binding in solution in terms of free
energy (G), enthalpy (H), and entropy (S) (4, 6, 63), where multiple sequen-
tial binding reactions are associated with a change in free energy (G), the
magnitude of which reflects binding affinity (6). Given the number of moles of
AR LBD in solution and the moles of peptide added during the titration,
stoichiometry and Kd can be obtained. The shape of the binding curve, i.e., the
fraction of bound versus free peptide, is a measure of cooperativity. The standard
free energy change for the AR LBD-peptide complex is related to the equilib-
rium association constant (Ka) (G  RT ln Ka). The free energy has enthalpic
(H) and entropic (S) components (G  H  TS) of which the former is
obtained with good accuracy from the magnitude of the thermal effect. The
entropy was calculated using the last equation.
LBD structure models. The space-filled models of the AR and ER LBDs
were determined based on previously published structural coordinates (48, 50)
and were modeled using the RASMOL program (49).
RESULTS
Effect of AR FXXLF motif-flanking charged residues in
binding the AR LBD. The FXXLF motif 23FQNLF27 in the
AR NH2 terminus binds AF2 in the presence of androgen,
resulting in the AR NH2-terminal and carboxyl-terminal N/C
interaction (19). Based on the cocrystal structure of the ER
LBD-TIF2 LXXLL peptide (50) and the predicted -helical
structure of the FXXLF motif, residues F23, L26, and F27 on
one face of the -helix are expected to contact the nonpolar
hydrophobic residues of AF2. The importance of these resi-
dues in AR-mediated transactivation was demonstrated previ-
ously (19). We tested several charged residues flanking the
FXXLF motif that are predicted to contact the LBD surface
near AF2 for their role in modulating the N/C interaction.
Deletion of residues carboxyl to the AR NH2-terminal FXXLF
core sequence in the GAL-AR FXXLF fusion peptides 16 to
30 and 20 to 30 increased binding to AR in a mammalian
two-hybrid assay using a GAL-luciferase reporter (Fig. 1A). In
contrast, no increase in activity was observed with deletion of
sequence amino-terminal to R20 in the fusion peptide GAL-
AR20-36. Changing R31 to alanine carboxyl-terminal to the
core sequence increased FXXLF motif binding, which was
increased further by replacing R31 with negatively charged
aspartic acid. The attenuating effect of R31 on FXXLF motif
binding to AF2 was supported by the ligand dissociation rate,
a property that reflects FXXLF motif binding to AF2 in the
N/C interaction in full-length AR (19). The dissociation half-
time of [3H]R1881 from AR-R31D determined at 37°C (120 
3 min) was slower than that for wild-type AR (98  3 min).
The results indicate that the attenuating effect of R31 on bind-
ing of FXXLF to AF2 detected in the peptide interaction assay
is also observed as part of the N/C interaction of full-length
AR.
A similar mutagenesis strategy was used to establish the role
of positively charged residues amino-terminal to the AR NH2-
terminal FXXLF motif. K17 is predicted to lie outside the
-helical region, and a deletion including this residue (Fig. 1A,
AR20-30) had little effect on the FXXLF interaction with AF2
in full-length AR. Similarly, changing K17 to alanine or aspar-
tic acid had little effect on binding of AR16-36 or AR16-30 to
AF2 (Fig. 1B). In contrast, changing R20 to alanine or aspartic
acid in these peptides and in AR20-30 reduced binding by
more than 50%. The data suggest that R20 and R31 contact
the AR LBD surface to modulate FXXLF motif binding at
AF2. R20 amino-terminal to the FXXLF core motif enhances
binding of FXXLF to AF2, whereas R31 carboxyl to the core
sequence weakens FXXLF motif binding to AF2. The flanking
residues R20 and R31 are therefore important in FXXLF
motif interaction with AF2 and have a role in mediating the
N/C interaction.
Charged clusters flanking AR AF2 mediate interactions
with the FXXLF and LXXLL motifs. The AR LBD crystal
structure (39, 48) and the ER-LXXLL motif cocrystal struc-
ture (50) suggest that F23 of the FXXLF motif contacts the
lower part of the AF2 hydrophobic surface (Fig. 2A), and L26
and F27 contact the upper part of the AF2 hydrophobic cleft.
The predicted ideal -helical structure of the FXXLF motif is
shown in Fig. 2B. Data presented above support these models
and place charged residues R20 and R31 flanking the FXXLF
motif (Fig. 2B) on the surface facing the hydrophobic residues
and thus are predicted to contact the flanking region of AF2
(Fig. 2A).
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FIG. 1. Effect of charged residues flanking the AR FXXLF in binding AR. (A) Mammalian two-hybrid assays were performed with HepG2 cells
by coexpressing GAL-AR peptides containing the GAL4 DNA binding domain (GAL4-DBD) and the indicated AR NH2-terminal FXXLF motif
amino acid wild-type or mutant sequence. GAL4-AR-FXXLF peptides (0.05 g) were cotransfected using Effectine (Qiagen) with pCMVhAR
(0.05 g) coding for full-length human AR and the 5XGAL4Luc3 reporter vector (0.1 g) in 12-well plates containing 0.2 	 106 HepG2 cells.
Transfected cells were incubated for 24 h in the absence and presence of 10 nM R1881 (methyltrienolone), a synthetic androgen. (B) Two-hybrid
peptide interaction assays were performed with HepG2 cells as described previously using GAL4-AR peptides with the FXXLF motif region with
wild-type or mutant sequence. The GAL-FXXLF peptide vectors with the indicated amino acid residue number and mutations were cotransfected
with pCMVhAR to test the role of positively charged residues NH2-terminal to the AR NH2-terminal FXXLF motif.
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We determined the functional importance of residues flank-
ing AF2 on the interaction with the FXXLF motif. The AF2
flanking region contains two oppositely charged amino acid
clusters. Two of the conserved residues, AR-E897 and AR-
K720, at opposite ends of AF2 in the AR LBD, are shared by
members of the steroid receptor family and correspond to
residues in estrogen receptor  (ER) and peroxisome prolif-
erator-activated receptor 
 (PPAR
) that were proposed to
function as a charge clamp, forming hydrogen bonds with the
peptide backbone of the LXXLL peptide (45). E897 was crit-
ical for AR transcriptional activation; however, K720 was rel-
atively unimportant (22). From the crystal structure of the AR
LBD (39, 48), E897 is positioned near E893 and E709, forming
a negative charge cluster on one side of AF2 (Fig. 2A). On the
opposite side of AF2, residues K720, K717, and R726 form a
positive-charge cluster (Fig. 2A). Using a mammalian two-
hybrid peptide interaction assay, we tested the functional im-
portance of these residues in the interaction with the AR
NH2-terminal FXXLF motif and the LXXLL motif of the p160
coactivators.
The AR FXXLF motif sequence in VP-AR1-660, a fusion
protein that contains the VP16 activation domain and AR
NH2-terminal region, binds AF2 in GAL-AR-LBD in the pres-
ence of androgen (Fig. 2C). Mutagenesis of several residues
flanking AF2 in GAL-AR-LBD showed that binding of the AR
FXXLF motif in VP-AR1-660 and the LXXLL motif region in
VP-TIF2.1 (TIF2 residues 624 to 1287) depended on each of
the negatively charged residues E709, E893, and E897 flanking
AF2. Mutation at E706 was less disruptive of binding. Muta-
tion of positively charged residues K717 and K720 indicated a
greater role in TIF2 LXXLL motif binding than in binding of
the AR FXXLF motif. The R726A mutation increased the
binding of VP-AR1-660 but had little effect on TIF2 LXXLL
motif binding. A triple mutant of the positive-charge patch
changing K717, K720, and R726 to alanine greatly increased
FXXLF binding but eliminated LXXLL binding.
The attenuating effect of R31 in AR FXXLF motif binding
shown above was also evident in the androgen-dependent N/C
interaction assay using the VP-AR1-660 and GAL-AR-LBD
(AR residues 624 to 919) fusion proteins. The R31D mutation
in VP-AR1-660 or a triple mutation to neutralize the lysine
and arginine residues in GAL-AR-LBD increased the AR N/C
interaction (Fig. 2D). This contrasted with the loss of binding
to an FXXAA mutant (Fig. 2D) that was shown previously to
eliminate FXXLF binding to AF2 (19). Surprisingly, binding of
the AR-R31D mutant was undetectable with the GAL-AR-
LBD triple mutant where the positive charges were neutral-
ized. This requirement for the positive-charge patch in AR-
R31D binding suggests properties similar to VP-TIF2.1 LXXLL
motif binding (see Fig. 2C).
The results indicate that negatively charged residues E709,
E893, and E897 flanking AF2 promote FXXLF and LXXLL
motif binding, whereas the positively charged cluster com-
prised of residues K717, K720, and R726 is required for TIF2
LXXLL motif binding but attenuates AR NH2-terminal
FXXLF motif binding. Furthermore, in addition to the AR
charge clamp residues E897 and K720 proposed previously for
corresponding residues in ER, additional charged residues
are required for AR recruitment of 160 coactivators and for
the FXXLF-mediated N/C interaction.
Role of polar charge distribution flanking the FXXLF and
LXXLL motifs in AR coregulators. Sequence alignment of the
FXXLF and LXXLL motif regions that mediate interaction of
several coregulatory proteins with AR indicates that positively
charged residues K and R predominate amino-terminal to the
core sequence, and negatively charged residues E and D pre-
dominate carboxyl-terminal to the core sequence (Fig. 3A).
The overall negative-to-positive charge ratios of the peptides
shown in Fig. 3A are 0.55 left and 3.5 right of the core se-
quence. To assess the charge distribution requirements for
FXXLF and LXXLL motif binding to AR, mutagenesis was
performed at residues (Fig. 3A) flanking the FXXLF motifs in
the AR coregulators ARA70, ARA54, and ARA55 (20, 25) as
well as in a D11 FXXLF peptide (7, 20) and SRC1 carboxyl-
terminal LXXLL-IV (44).
In two-hybrid interaction assays using full-length AR, muta-
tions to alanine at two positively charged residues, K327 and
K329, reduced binding of the ARA70 FXXLF motif to AR
compared to the wild-type control (Fig. 3B). A further reduc-
tion in luciferase activity was seen when these residues were
changed to aspartic acid. A requirement for positively charged
residues amino-terminal to the core motif was supported by
the interaction of the D11-FXXLF R7D mutant peptide, by
SRC1-IV mutations to alanine at K1432 and E1441, and by the
activity of a second double mutant (K1432E/E1441K) in which
the positions of the positively and negatively charged residues
were exchanged. The contribution of negative charges carbox-
yl-terminal to the core sequence was less evident with the
D16R mutation in D11-FXXLF. Binding of the D11-FXXLF
peptide depended instead on R7, amino-terminal to the core
FIG. 2. Effect of charge clusters flanking AF2 in the AR LBD on AR-FXXLF and TIF2-LXXLL motif binding. (A) A space-filled model of
the DHT-bound AR LBD is based on structural coordinates of rat AR646-901 (48), which has amino acid sequence identical to that of human
AR664-919 (37). Positively charged residues K717, K720, and R726 flanking AF2 are shown in blue, negatively charged residues E709, E893, and
E897 are shown in red, and AF2 hydrophobic residues are shown in yellow. DHT bound in the core structure would not be evident on the surface.
(B) Ideal -helical structure of the AR NH2-terminal FXXLF motif. The model helix was built using the Biopolymer module of the InsightII
molecular modeling system from Accelrys Inc. (www.accelrys.com). (C) Two-hybrid assays were performed with HepG2 cells using GAL-AR-LBD
(0.15 g) coding for the GAL4 DNA binding domain fused to AR LBD containing residues 624 to 919 with wild-type (WT) or the indicated mutant
sequences. GAL-AR-LBD was cotransfected with the 5XGAL4Luc3 reporter vector (0.1 g) and VP-AR1-660 (0.15 g) containing the VP16
transactivation domain and AR NH2-terminal residues 1 to 660 or VP-TIF2.1 containing the three-LXXLL motif region in TIF2. Assays were
performed with HepG2 cells in the absence and presence of 10 nM R1881. (D) Two-hybrid assays were performed using VP-AR1-660 containing
wild-type sequence or the 23FQNLF27-to-FQNAA (FXXAA) or R31D mutation. GAL-AR-LBD expressed residues 624 to 919 with wild-type
sequence or with a triple mutation, K717A/K720A/R726A, as indicated. HepG2 cells were cotransfected with wild-type and mutant VPAR1-660
together with wild-type or mutant GAL-AR-LBD and the 5XGAL4Luc3 reporter vector. Cells were incubated for 24 h in the absence and presence
of 10 nM 1881, and numbers of luciferase optical units were determined.
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sequence. The double mutant R7D and D16R in D11-FXXLF
almost eliminated binding to AR. Binding of the most strongly
AR-interacting peptide, ARA54 (20), was greatly reduced by
changing D462 to arginine or changing V461, D462, and V463
to arginine on the carboxyl-terminal side of the core sequence.
The results, in agreement with results of the AR FXXLF motif,
indicate that flanking positively charged residues amino-termi-
nal to the FXXLF core sequence or negatively charged resi-
dues carboxyl-terminal to the FXXLF core sequence promote
motif binding to AF2.
The relative importance of complementary charge groups
flanking the FXXLF peptides and AF2 was well supported by
AR binding of the AR coregulator ARA54 and ARA70
FXXLF motifs. ARA54 lacks positively charged residues ami-
no-terminal of the core sequence (Fig. 3A) and depended
instead on negatively charged D462 carboxyl-terminal to the
core sequence for FXXLF motif binding (Fig. 3B). As a result,
the AF2 positively charged K720 residue was required for
ARA54 FXXLF motif binding, but the negative cluster E709
and E893 was not, since AR-K720A but not AR-E709K/E893K
eliminated ARA54 FXXLF motif binding (Fig. 3C). Con-
versely, ARA70 lacks flanking negatively charged residues car-
boxyl-terminal to the FXXLF motif (Fig. 3A). Binding of
ARA70 to AF2 depended on residues K327 and K329 amino-
terminal and within the FXXLF motif (Fig. 3B) as previously
reported (64) and on AR AF2 residues E709 and E893, but not
on K720 (Fig. 3C). The data demonstrate that negatively
charged residues flanking AF2 mediate interactions with pos-
itively charged residues amino-terminal of the FXXLF core
motif, and positively charged residues flanking AF2 mediate
interactions with the negatively charged residues carboxyl to
the FXXLF core motif.
Charge distribution requirements for binding of the LXXLL
motif to steroid receptors. The LBD of the AR, glucocorticoid
(GR), progesterone (PR), and mineralocorticoid receptors are
closely related structurally with conservation of the positively
and negatively charged clusters flanking AF2 (1, 58, 59, 61).
ER and ER are less related to this group but have a charge
polarity flanking AF2 that resembles that for AR (Fig. 2A; also
see Fig. 5A). ER differs from ER in lacking D545, and R363
is replaced by lysine (32). We tested whether the charge re-
quirements identified for binding of the FXXLF motif to AR
AF2 apply to binding of the p160 coactivator LXXLL motif to
other steroid receptors.
The negative-to-positive charge ratios flanking the p160 co-
activator LXXLL motifs shown in Fig. 4A are 0.31 left of the
core motif and 2.9 right of the core sequence. These ratios are
similar to those flanking the FXXLF motifs shown in Fig. 3A
(0.55 and 3.5, respectively). The charge requirements for bind-
ing of the p160 coactivator LXXLL motif to other full-length
steroid receptors were tested by mutagenesis of residues flank-
ing the LXXLL motifs (circled in Fig. 4A). GR and PR pref-
erentially bind the third TIF2 LXXLL motif (TIF2-LXXLL-
III) relative to the other LXXLL motifs, whereas ER and
ER preferentially bind TIF2-LXXLL-II (data not shown) and
were tested accordingly. Converting D753 to arginine in the
TIF2-LXXLL-III peptide, a residue that corresponds to R31
flanking the AR FXXLF motif, abolished LXXLL motif bind-
ing to full-length GR and greatly reduced binding to PR (Fig.
4B). Converting D696 to arginine in TIF2-LXXLL-II reduced
binding to ER and ER. A double mutant in TIF2-LXXLL-
II, converting H687 and K688 to aspartic acid, abolished bind-
ing to ER and ER (Fig. 4B). The data provide strong evi-
dence for a polar charge distribution for optimal LXXLL motif
binding to AF2 in other steroid receptors. The data indicate a
requirement for positively charged residues amino-terminal to,
and negatively charged residues carboxyl-terminal to, the
LXXLL core sequence and support the functional importance
of complementary charge polarity in FXXLF and LXXLL mo-
tif-mediated coactivator recruitment.
The ER AF2 region is flanked by positively and negatively
charged clusters similar to that observed for AR (Fig. 2A and
5A). ER AF2-flanking residues E542 and K362 were shown
previously to be required for SRC1 LXXLL motif binding (26,
50). Two-hybrid assays were performed using a GAL fusion
peptide containing the second LXXLL motif of TIF2 (GAL-
TIF2-LXXLL-II) or the first LXXLL motif of TRAM1 (GAL-
TRAM-LXXLL-I) and VP-ER-LBD with wild-type and
mutant sequence. The TIF2 second LXXLL motif and the
TRAM1 (ACTR) first LXXLL motif are the principal binding
motifs that mediate recruitment by ER (10). We show here
for TIF2 LXXLL-II that in addition to the conserved charge
clamp residues, ER AF2-flanking residues E380, D538, D545,
and R363 are important for LXXLL motif binding (Fig. 5B).
For TRAM1 LXXLL-I, the conserved charge clamp residue
E542 is not important, while E380, D538, and D545 are re-
quired for binding (Fig. 5C). The results support the steroid
receptor family requirement for charged residues flanking AF2
FIG. 3. Requirement for charged residues flanking the FXXLF and LXXLL motifs in AR coregulator interaction with AR. (A) FXXLF and
LXXLL motifs and flanking sequence of regions that bind AR AF2. Shown are human AR amino acid residues 16 to 34 that contain the FXXLF
motif sequence 23FQNLF27, which mediates the N/C interaction (19), and the FXXLF motif regions from AR coregulators ARA70 (residues 321
to 339), ARA54 (residues 447 to 465), and ARA55 (residues 314 to 332) (20). Also shown are the D11-FXXLF peptide (20) and SRC1
carboxyl-terminal LXXLL-IV motif (residues 1428 to 1441) (47). Consensus residues of the binding motifs are shaded, and the relative positions
of amino acids are numbered from the start of the core sequence. Residues that were mutated are circled. Basic residues K and R are shown in
blue, and acidic residues D and E are shown in red. (B) Two-hybrid peptide interactions with AR. The GAL-ARA70 peptide contained ARA70
residues 321 to 340 with wild-type or mutant sequence as indicated. GAL-D11-FXXLF contained sequence derived from the D11-LXXLL peptide
(44) that was changed to an FXXLF motif (20) with wild-type or mutant sequence. Numbering of the D11 peptide was left to right from the
beginning of the peptide. The GAL-ARA54 peptide contained residues 447 to 465 with wild-type or mutant sequence. GAL-SRC1-IV contained
residues 1428 to 1441 including the fourth and carboxyl-terminal LXXLL motif with WT or mutant sequence. GAL peptide vectors were
cotransfected with pCMVhAR coding for full-length human AR and the 5XGAL4Luc3 reporter vector in HepG2 cells as described. Cells were
incubated in the absence and presence of 10 nM R1881 for 24 h, and numbers of luciferase optical units were determined. (C) Two-hybrid
interaction assays were performed as described above using full-length wild-type AR and AR mutants E709K/E898K or K720A, cotransfected
either with empty parent vector (GAL4-DBD-0) or with the GAL4-DBD-peptide fusion proteins. These were cotransfected with GAL-ARA54-
447-465 or GAL-ARA70-321-340. Luciferase activity was determined in the absence and presence of 10 nM R1881 as shown.
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in LXXLL motif binding. In addition, the previously reported
charge clamp residue E542 in ER is not required for all
coactivator LXXLL motif binding.
Charge distribution requirements for nonsteroid nuclear
receptors. We tested whether a similar polar charge distribu-
tion was required for binding of the LXXLL motif to non-
steroid nuclear receptors, where the AF2 sites have a less
distinct pattern of charged residues relative to the steroid re-
ceptors (2, 13). We tested binding of the most strongly inter-
acting LXXLL motifs of TIF2 and SRC1 as GAL-peptide
fusions in binding assays with full-length TR, the vitamin D
receptor (VDR), and RXR (Fig. 6). Replacing aspartic acid
with arginine carboxyl-terminal to TIF2-LXXLL-II (D696R)
and TIF2-LXXLL-III (D753R) reduced binding to TR and
VDR, respectively. In contrast, this mutation (D753R) slightly
increased binding of TIF2-LXXLL-III to RXR. Changing
residues H687 and K688 to aspartic acid amino-terminal to
TIF2-LXXLL-II abolished binding to TR but increased bind-
FIG. 4. Flanking charged residue requirements of p160 coactivator LXXLL motif binding to steroid receptors. (A) Amino acid sequence of the
LXXLL motif regions in the human p160 coactivators SRC1 (47), TIF2 (29, 56), and TRAM1 (53). Basic residues K, R, and H are shown in blue,
and acidic residues D and E are shown in red. The conserved LXXLL motif is shaded, and the residues that were mutated are circled. The LXXLL
motifs are numbered relative to the start of the core motif. (B) Two-hybrid interaction assay of TIF2-LXXLL peptides II and III with full-length
steroid receptors. GAL fusion peptide vectors coding for TIF2-LXXLL-II and TIF2-LXXLL-III were cotransfected with the 5XGAL4Luc3
reporter vector and expression vectors for GR (pCMVhGR), PR-A (VP-PR-A), ER (VP-ER-LBD coding for residues 312 to 595), and ER
(VP-ER full-length residues 1 to 530). Transfected HepG2 cells were incubated in the absence or presence of 10 nM dexamethasone for GR,
10 nM R5020 for PR-A, and 1 M 17-estradiol for ER and ER.
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ing to RXR. Neutralizing or reversing the charges flanking
SRC1-LXXLL-IV (K1432 and E1441 to alanine or exchanging
the charge positions) had little influence on RXR binding
(Fig. 6). A triple mutation, H631D/K632D/E642R, in SRC1
LXXLL-I or a double mutation, K640D/D650R, in TIF2
LXXLL-I abolished the interaction with RXR. The results
indicate that the requirements for complementary charge po-
larity that mediates AF2 interaction with the LXXLL motif
apply to TR and VDR but apply less well to the nonsteroid
nuclear receptor RXR.
Binding affinity of the FXXLF and LXXLL motifs for the AR
LBD. We used isothermal titration calorimetry to measure the
equilibrium binding affinities and thermodynamic properties of
binding of the AR LBD to the FXXLF peptides derived from
ARA54 and the AR NH2-terminal domain and to LXXLL-III
from TIF2/GRIP1 (Fig. 7). Measurements were made by se-
quential injections of peptide into solutions containing the AR
LBD. As the peptide-AR LBD titration progressed and the
AR LBD became saturated, less of the added peptide com-
bined with the AR LBD and the thermal effect was smaller.
From the change in thermal effect during the course of titra-
tion, the equilibrium dissociation constant, Kd, was computed
by standard methods (6). The data indicate the presence of a
single binding site with no clear sign of cooperativity, with a Kd
of 0.9 to 1.2 M for the two FXXLF peptides and 6.0 M for
TIF2-LXXLL-III. Binding of the AR FXXLF NH2-terminal
core peptide to the LBD had a greater enthalpic term (H 
5.7 kcal/mol) (Table 1) than was observed with TIF2
LXXLL-III (H  1.8 kcal/mol). The entropy (S) was 1.4
and 7.9 cal/mol for FXXLF peptide binding compared to 18.1
cal/mol for the TIF2 LXXLL-III peptide.
A possible interpretation of these changes is as follows.
Consider the binding of the ARA54-FXXLF and TIF2-
LXXLL-III peptides to the AR LBD (Table 1) that differed
the most in G. The G value was about 1 kcal/mol, which was
small but significant. ARA54-FXXLF (Kd  0.9 M) was more
tightly bound than TIF2-LXXLL-III (Kd  6 M) to the AR
LBD, in agreement with the two-hybrid results. A negative H
means that heat is produced as a result of the binding reaction.
The difference in H of these two peptides was much larger
than the difference in G and suggests fewer contacts, perhaps
between polar groups for the TIF2-LXXLL-III peptide-AR
LBD complex. The positive change in entropy, which produces
a largely compensating term TS in the free energy, indi-
cates that the weaker TIF2-LXXLL-III-AR LBD complex is
less ordered, which is not an unreasonable conclusion if fewer
contacts are present. A more tightly bound FXXLF-AR LBD
complex would be more rigid and therefore would have lower
entropy, whereas a less tightly bound peptide, such as TIF2-
LXXLL-III, would have fewer favorable contacts, be more
disordered, and have greater entropy.
DISCUSSION
Charge clamp residues. The opposite ends of the AF2 hy-
drophobic groove in the LBD of nuclear receptors contain two
highly conserved charged residues. These so-called charge
clamp residues are thought to assist in orienting LXXLL motif
binding to AF2. K362 in ER was initially shown to be highly
conserved among nuclear receptors and required for transcrip-
tional activity and coactivator recruitment (26). It was sug-
gested that K362 is the only essential positively charged residue
in the predominantly hydrophobic coactivator binding surface
(26, 38). ER also contains E542 separated from K362 by 15
Å, which is sufficient to accommodate the 11-Å axial length of
the LXXLL binding region (50). Interaction of the LXXLL
motif with the AF2 core is stabilized by these highly conserved
charged residues.
Here we present evidence that additional, well-ordered
charged residues are present flanking AF2 in the AR LBD that
facilitate coactivator recruitment and binding specificity. The
increased number of charged residues adjacent to AF2 in AR
is conserved in GR and PR relative to other nuclear receptors
(3, 61). The importance of these residues was recently demon-
strated by the cocrystal structure of an F602S glucocorticoid
LBD mutant bound to dexamethasone and the LXXLL-III
peptide of TIF2 (3). The mutation was introduced to increase
solubility of the GR LBD necessary for its purification while
retaining wild-type transcriptional activity. In addition to the
conserved GR residues E755 in helix 12 and K579 in helix 3,
which correspond to the first reported charge clamp, the
charged residues R585 and D590 in human GR are conserved
in human AR (R726 and D731) and human PR (R740 and
D745) and contribute to the specificity of LXXLL motif bind-
ing (3). In the cocrystal structure of the GR LBD and the
LXXLL-III peptide, these residues form hydrogen bonds with
R  2 within the core motif and D  6 in the p160 coactivator,
where L  1 is the first residue of the care motif. Based on GR
crystal results, D731 in the AR LBD may form a second charge
clamp with residue R  2 of TIF2-LXXLL-III, K  2 of
ARA70, or R  3 of ARA54. However, D731 will not form this
interaction with the AR NH2-terminal FXXLF motif because
of the absence of a positively charged residue at the 2 or 3
position.
We show that the initially reported charge clamp residue
flanking AF2 in the ER LBD that forms hydrogen bonds with
the peptide backbone does not fully account for LXXLL motif
binding. E542 in ER is required for binding LXXLL-II of
TIF2 (Fig. 5A) and TRAM1 (data not shown), but not for
binding LXXLL-I of TRAM1. TIF2 LXXLL-II and TRAM1
LXXLL-I and II bind ER to a similar extent based on two-
hybrid interaction results (data not shown). K362 was also not
required for RIP140 LXXLL motif binding (26).
Similarities exist in the first reported charge clamp residues
adjacent to AF2 in other receptors. K362 and E542 in ER
correspond to K288 and E457 in TR-1 (11), K292 and E462
in PPAR (62), and K301 and E471 in PPAR
 (45), each
facilitating tight hydrophobic packing of LXXLL helix residues
in the LBD pocket. Crystallographic evidence indicates that
the glutamic acid in helix 12 forms hydrogen bonds to back-
bone amides of leucine 1 of the LXXLL motif and the amino-
terminal adjacent residue, whereas lysine in helix 3 forms hy-
drogen bonds to the backbone carbonyls of leucine 4 and 5
of the motif (45). E471 in one PPAR
 monomer forms
hydrogen bonds with K632 and L633 in SRC1 LXXLL-I
(632KLVGLLTT639) and with K688, I689, and L690 in SRC1
LXXLL-II (688KILHRLL693) in the second monomer of the
PPAR
 dimer (45). Two LXXLL motifs in the same SRC1
molecule interact with both LBDs to stabilize the PPAR-RXR
and RXR-RAR heterodimers and are dependent on the
VOL. 23, 2003 CHARGE POLARITY MODEL FOR COACTIVATOR RECRUITMENT 2143
spacer distance between the motifs (15, 60). Shared binding of
motifs by a receptor dimer has not been demonstrated with
steroid receptors.
One function of the charged residues is in “helix capping”
through hydrogen bonding to stabilize the hydrophobic inter-
action of the LXXLL motif with the AF2 core and to limit the
length of the LXXLL motif amphipathic helix (11, 45, 50). In
the absence of coactivator, the side chains of these charged
residues are exposed to the solvent (5). However, in contrast to
the steroid receptors, the crystal structures of PPAR
 (45) and
RXR (13) show a less organized pattern of charged residues
and lack the additional positive and negative charge clusters
that characterize the AF2 regions of AR, GR, and PR.
Whether the primary role of the charge clusters flanking AF2
is in stabilizing the LXXLL helix and/or facilitating initial
LXXLL helix binding, these charged residues are clearly in-
dispensable to coactivator recruitment.
Residues flanking the LXXLL/FXXLF motifs. p160 coacti-
vator LXXLL motif binding shows specificity for nuclear re-
ceptors (40) in LXXLL motif preference, the number and
spacer distance between LXXLL motifs (11, 12, 40), and in the
contribution of flanking sequence. Here we show that the
charge requirements of sequence flanking the FXXLF and
LXXLL motifs adhere to the following criteria for AF2 bind-
ing. Positively charged residues are favored at position 1, 2,
or 3 relative to the FXXLF and LXXLL core sequence
(where the first F and L are 1, respectively) and/or negatively
charged residues at position 8 or 9. Charged residues ami-
no- and carboxyl-terminal of the motif apparently function
alone or together to facilitate coactivator binding. Neutral or
positively charged residues occur at positions 2 and 3
within the core motifs, with neutral or negatively charged res-
idues at 6 and 7. These criteria for FXXLF and LXXLL
motif binding to AF2 are supported by the classification of
high- and low-affinity LXXLL peptides (24) and for LXXLL
peptides obtained by phage display (7) and apply to the nuclear
receptor family, including TR and VDR but to a less extent
for nuclear receptor RXR.
In addition to the experimental evidence presented for AR,
other evidence supports these protein interaction criteria. Ly-
sine residues amino-terminal to LXXLL-I and -II correspond
to R20 flanking the AR FXXLF motif but occupy slight-
ly different positions. Early studies on ER indicated that
neutralization of a basic residue amino-terminal to SRC1
LXXLL-II did not diminish coactivator binding (38), and spec-
ificity depended only on motif sequence (24). However, three
basic residues amino-terminal to the core LXXLL motif facil-
itated docking of the LXXLL motif (38). The PPAR
 LBD-
LXXLL peptide cocrystal structure indicates that these lysine
residues are solvent exposed and do not directly contact
PPAR
 (45). Similarly, the carboxyl-terminal L636 and T639
of SRC1 LXXLL-I and L693 and L694 of LXXLL-II form
hydrogen bonds with a highly conserved K301 in the PPAR

LBD, which corresponds to K720 in AR. Hydrogen bonds in
the PPAR
-coactivator peptide complex form with backbone
amides of the LXXLL motifs and backbone carbonyls in the
LBD. Charged residues D590 and R585 in the GR LBD form
hydrogen bonds with side chains of R  2 and D  6 in the
LXXLL-III motif of TIF2. Mutation of GR D590 and R585 to
alanine and the charged residues flanking LXXLL-III of TIF2
reduced the peptide interaction and transactivation by the GR
LBD (3). The 
-carboxylate group of E542 in ER forms a
hydrogen bond(s) to amides in the LXXLL-II helix, and the
ε-amino group of K362 forms a hydrogen bond(s) with carbon-
yls in the LXXLL helix (50).
Binding affinity of the core AR NH2-terminal FXXLF pep-
tide to the AR LBD (Kd, 1.2 M) measured by isothermal
titration calorimetry is fivefold higher than the affinity for the
LXXLL-III motif of TIF2 (6.0 M). Calorimetry measure-
ments support the two-hybrid interaction data and indicate
preferential AR binding of the FXXLF motif over the pre-
ferred LXXLL-III motif of TIF2. The AR LBD binding affin-
ities for the FXXLF motifs are in the same range as LXXLL
motif binding by other receptor LBDs. The binding affinity of
GRIP1 LXXLL-II to TR (Kd, 0.8 M) was higher than the
binding affinity for LXXLL-III (Kd, 3.2 M) and LXXLL-I (30
M) measured by GST fusion protein affinity in vitro binding
(11). Binding of LXXLL-I and -II with TR showed that the
flanking sequence of LXXLL-II contributes to higher-affinity
binding (11). A 13-residue peptide containing LXXLL-II binds
the agonist-bound ER LBD with a 50% inhibitory concen-
tration of 0.4 M (50). Positively charged residues amino-
terminal to the LXXLL motif interacted favorably with nega-
tively charged residues carboxyl-terminal in the TR LBD
(11). Binding of GRIP1 LXXLL-III to GR and AR was in-
creased by GRIP1 residues 1011 to 1121, suggesting that ad-
ditional contacts with the LBD facilitate coactivator binding to
nuclear receptors (28) and that binding affinities determined
using short peptides may underestimate the strength of coac-
tivator interactions. Considering the local concentration of the
AR NH2-terminal FXXLF motif in the AR dimer bound to
androgen response element DNA and the higher affinity of the
FXXLF motif, competitive inhibition of p160 coactivator bind-
ing might result from the androgen-induced N/C interaction.
Indeed, experimental evidence supports this androgen-depen-
dent competitive inhibition of p160 coactivator binding by the
AR NH2-terminal FXXLF motif (18).
Electrostatic interactions in p160 coactivator recruitment.
We propose that additional charged residues both in the ste-
roid receptor LBD on opposite sides of the hydrophobic core
of AF2 and flanking the FXXLF and LXXLL motif regions are
involved in an electrostatic attractive mechanism to recruit the
p160 coactivators (Fig. 8). Negatively charged residues carbox-
yl-terminal to the FXXLF and LXXLL motifs and positively
FIG. 5. Role of charged residues flanking AF2 in ER LBD in TIF2-LXXLL-II binding. In panel A, the space-filled model of the ER LBD
was based on structural coordinates of ER amino acids 297 to 554 in the presence of diethylstilbestrol (50). Positively charged residues K362 and
R363 are shown in blue, negatively charged residues E380, D538, E542, and D545 are shown in red, and AF2 hydrophobic residues are shown in
yellow. Two-hybrid peptide interaction assays were performed by cotransfecting the 5XGAL4Luc3 reporter vector, VP-ER-LBD with wild-type
(WT) or mutant sequence, with either GAL-TIF2-LXXLL-II (B) or GAL-TRAM1-LXXLL-I (C). Cells were incubated in the absence and
presence of 1 M 17-estradiol (E2), and luciferase activity was determined as described in Materials and Methods.
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charged residues amino-terminal to the core motifs interact
with oppositely charged residues adjacent to AF2 so that the
hydrophobic interaction between the AF2 core region and the
conserved LXXLL motif is complemented by electrostatic in-
teractions. In the case of AR and as recently shown for GR,
charge clusters formed by additional residues near AF2 appear
to contribute to the affinity and specificity of coactivator bind-
ing. This electrostatic attraction model provides a mechanistic
explanation for different nuclear receptors showing prefer-
ences for LXXLL motif binding (11, 28, 40). Further, in AR
the orientation of binding of the FXXLF motif to AF2 may be
established in part by attractive forces that cause formation of
an antiparallel dimer.
The charge polarity model can account for several previ-
ous observations relating to coactivator recruitment. TIF2-
LXXLL-II mutations changing H687 and K688 to aspartic acid
disrupted binding of the LXXLL motif to ER. The cocrystal
structure of the TIF2-LXXLL-II peptide-ER LBD showed
that LXXLL motif residues H687 and K688 at positions 2
and 3 relative to the core sequence directly contact AF2
residues E542 and E380 in the ER LBD (50). The charge
polarity model for FXXLF and LXXLL motif recruitment by
AF2 also explains the weak interaction of the AR coregulatory
protein ARA55 (20). D320 in position 1 and R328 in position
8 of the FXXLF core peptide of ARA55 are predicted to cause
charge repulsion at the AR AF2 surface. Binding of the
ARA55 FXXLF peptide to AR AF2 was negligible in mam-
malian two-hybrid assays (20). Reversing the charge distribu-
tion in an ARA55 peptide double mutant increased binding to
AF2 by threefold over that of the wild-type ARA55 control
(data not shown).
The influence of charge interactions in recruiting the
FXXLF or LXXLL motifs of coactivators and mediating the
AR N/C interaction makes posttranslational modification of
flanking charged residues a potential regulatory mechanism
for hormone-induced gene transcription. The charge polar-
ity model proposed here for coactivator recruitment is con-
sistent with the effect of acetylation on ER interaction with
LXXLL-I of ACTR (10). Acetylation of K629 and K630 im-
mediately preceding LXXLL-I of ACTR neutralizes the posi-
tive charges and terminates hormone-induced gene activation
by causing dissociation of the receptor-bound p160 coactivator.
FIG. 6. Role of charged residues flanking the LXXLL motifs in binding nonsteroid nuclear receptors. Two-hybrid interaction assays were
performed using TIF2 and SRC1 LXXLL peptides with TR, VDR, and RXR. GAL-TIF2-LXXLL-I, -II, and -III or GAL-SRC1-LXXLL-I and
-IV expression vectors coding for wild-type or mutant sequence were cotransfected with pCMX-VP-F-hTR, pVP16-VDR, or VP16-hRXR. Cells
were incubated in the absence and presence of 1 M triiodothyronine for TR, 100 nM 1,25-dihydroxyvitamin D for VDR, and 1 M 9-cis-retinoic
acid for RXR for 24 h prior to determining luciferase activity. Basic residues K, R, and H are shown in blue, and acidic residues D and E are
shown in red.
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In support of the model proposed here, it was speculated that
the AF2-flanking charged residues E380 in helix 5 and D538 in
helix 12 of ER are involved in the electrostatic recruitment of
oppositely charged residues flanking the LXXLL motif in
ACTR (10). Similarly, phosphorylation of serine or threonine
could alter an electrostatic interaction by introducing a nega-
tive charge. We found that mutations in ARA70 that converted
two candidate phosphorylation sites, T324 and S325, to aspar-
tic acid disrupted FXXLF motif binding to AR (data not
shown). Phosphorylation of S884 carboxyl-terminal to the
LXXLL motif of TRBP defined its selectivity for ER and
TR coactivator binding (31). Thus, the charge polarity model
for coactivator recruitment and for the N/C interaction ap-
pears to establish an additional regulatory mechanism for ste-
roid hormone action.
Charge-driven reactions were postulated previously in the
heterodimerization and coactivator recruitment of the RXR/
PPAR
 heterodimer (15). The asymmetric intradimer interac-
tion that occurs within RXR is facilitated by a salt bridge
between E352 and R348, both in helix 7 of RXR, and is
strengthened by the presence of E431 in helix 10. An inter-
dimer salt bridge occurs between K431 in helix 10 of RXR
with carboxyl-terminal Y477 in the AF2 helix 12 of PPAR
. In
addition, K356 in RXR interacts with a negatively charged
region at E407 on the surface of PPAR
 (15). Residues flank-
ing the LXXLL motifs may also be involved in salt bridge
formation and contribute to nuclear receptor specificity of
coactivator recruitment, although these residues did not form
structure in the PPAR
-coactivator peptide cocrystal (45).
These multiple-charge interactions and salt bridges in the
PPAR
/RXR heterodimer between oppositely charged resi-
dues promote coactivator recruitment to AF2 and support the
role of electrostatic interactions in LXXLL motif binding.
The AR-specific FXXLF motif. The attenuating effect of R31
carboxyl-terminal to the AR NH2-terminal FXXLF motif in
the AR N/C interaction appears to result from charge repul-
sion at the positively charged patch formed by K720, K717, and
R726 flanking AF2. Comparison of the cocrystal structure of
the TIF2-LXXLL-II peptide with the ER LBD (50) and the
predicted -helical structure of the AR FXXLF motif suggests
FIG. 7. Isothermal titration calorimetry measurements of FXXLF and LXXLL peptide binding to the AR LBD. Binding parameters were
determined as described in Materials and Methods by titrating ARA54 FXXLF peptide 447-NDPGSPCFNRLFYAVDVDD-465 (A), the AR
NH2-terminal FXXLF peptide 20-RGAFQNLFQSV-30 (B), and the TIF2 LXXLL-III peptide 738-KKKENALLRYLLDKDDTK-755 (C) into
solutions containing human AR LBD fragment (amino acid residues 663 to 919). Multiple sequential injections (50, 50, and 30, respectively) were
performed for each of the peptide-AR LBD interactions. Thermograms are shown in the upper panels, and binding isotherms are shown below.
TABLE 1. Thermodynamic properties of AR LBD binding of FXXLF and LXXLL peptides by isothermal titration calorimetry at 26°Ca
Peptide Kd (M) Ka (105 M1) H (kcal/mol) S (cal/mol) G (kcal/mol) N
ARA54-FXXLF 0.9  0.2 11.7  1.5 8.7  2.3 1.4  7.3 8.3  0.1 1.0  0.3
AR-NH2-FXXLF 1.2  0.2 8.4  0.2 5.7  1.2 7.9  4.5 8.1  0.1 1.1  0.1
TIF2-LXXLL-III 6.0  1.1 1.7  0.3 1.8  0 18.1  0.5 7.2  0.1 1.4  0.2
a Binding parameters were determined as described in Materials and Methods and the legend to Fig. 7 by titrating ARA54 FXXLF peptide residues 447 to 465, AR
NH2-terminal FXXLF peptide residues 20 to 30, and TIF2 LXXLL-III peptide residues 738 to 755 with the AR LBD using isothermal titration calorimetry. N, number
of peptide binding sites per LBD.
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that AR R31 lies toward the AF2 surface in the androgen-
dependent N/C interaction, where it can be influenced by the
positively charged cluster in the LBD. TIF2-LXXLL-III has
aspartic acid at position 9 rather than R31 in the AR FXXLF
motif, which provides an explanation for disruption of TIF2
binding by the AR-K720A mutant (22). K362 in ER corre-
sponds to AR K720, which is also required to recruit p160
coactivators (22, 26). R31 is conserved among vertebrate AR
and Xenopus in an otherwise poorly conserved AR NH2-ter-
minal region, suggesting an important function (21). Charge
repulsion between R31 flanking the AR NH2-terminal FXXLF
motif and the positively charged AF2 patch constrains the
androgen-induced N/C interaction. Because the AR N/C in-
teraction competes with and represses p160 coactivator re-
cruitment at AF2 (18), a less-than-optimal AR N/C interaction
could allow coactivator access to AF2 under certain cell con-
ditions. Recruitment of overexpressed p160 coactivators by
AR AF2 may occur in recurrent prostate cancer (17).
It could be argued that the AR NH2-terminal FXXLF motif
serves as an intra- or intermolecular mimic of the LXXLL
motif. But unlike a similar role for the LXXML motif in helix
12 of ER that binds to AF2 in the presence of antagonist, the
FXXLF motif binds AF2 in the AR LBD specifically in the
presence of the biologically active androgens, testosterone and
dihydrotestosterone (19), and the synthetic anabolic steroids
(30). Interaction of FXXLF with AF2 may contribute to the
predominant activity of the NH2-terminal activation function 1
in AR. Considering the high affinity of FXXLF motif binding
relative to the LXXLL motifs of p160 coactivators and its local
concentration during AR dimerization and DNA binding, nor-
mal physiological levels of p160 coactivators may not activate
AR through AF2.
In conclusion, the LBDs of nuclear receptors contain tran-
scriptional activation domains that form similar highly struc-
tured arrangements of -helices in response to hormone bind-
ing. As an activation domain, the LBD is large (250 amino
acids) compared to smaller unstructured activation domains
(36). The AF2 active surface of the nuclear receptor LBD is
made up of hydrophobic and charged residues which are
brought together by agonist binding (57). Transcriptional ac-
tivation domains of mammalian regulatory proteins generally
have little sequence homology and occur as random coils that
acquire secondary structure after binding coactivators. Of the
acidic, glutamine-rich and proline-rich classes of transcrip-
tional activation domains (42), acidic activation domains en-
riched in aspartic and glutamic acid residues have been studied
most extensively (54). Site-directed mutagenesis revealed that
hydrophobic residues are critical for function and individual
acidic residues are less important. Binding of coactivators in-
duces acidic activation domains to form amphipathic -helices
(55). A two-step model proposed for acidic activation domains
involves long-range interactions between negatively charged
residues of an unstructured activation domain and positive
charges of a coactivator to initiate recruitment. An amphi-
pathic -helix is then induced in the activation domain, and
stable hydrophobic interactions occur with the coactivator
(27). Based on studies in this report, a model for coactivator
recruitment by steroid receptors is presented in which the
recruitment of FXXLF and LXXLL coactivator motifs by the
AF2 region of steroid receptors reflects a reversal of the acidic
FIG. 8. Schematic diagram of the charge polarity interaction model for steroid and nuclear hormone receptor recruitment of coactivators and
for the AR N/C interaction. Hormone binding induces the formation of the AF2 hydrophobic cleft on the surface of the LBD that is flanked by
clusters of oppositely charged residues. The charge patches on either side of AF2 interact with charged residues flanking the FXXLF or LXXLL
motif sequences to mediate the androgen-dependent N/C interaction or steroid receptor coactivator recruitment. The less-ordered FXXLF or
LXXLL motif is recruited to the AF2 interaction surface by complementary charges on either side of AF2, resulting in stabilization of the -helix
interface at the AF2 hydrophobic cleft.
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transcriptional activation domain-coactivator interaction mod-
el. Charge interactions between unstructured coactivator bind-
ing motifs and clusters of oppositely charged residues in the
highly structured AF2 region initiate the orientation and
recruitment of FXXLF and LXXLL motif binding by AF2.
Subsequent hydrophobic residues of the FXXLF and LXXLL
amphipathic helix establish nonpolar contacts with the hydro-
phobic cleft of AF2 to stabilize the receptor-coactivator com-
plex. In both models, charge interactions initiate binding be-
tween structured and unstructured interacting partners.
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